REVELATION BIOSCIENCES, INC.: 10-K filed 2021-03-31

Name: REVELATION BIOSCIENCES, INC.: 10-K filed 2021-03-31
Creator: REVELATION BIOSCIENCES, INC.

What REVELATION BIOSCIENCES, INC. reported in its annual report filed 2021-03-31 (fiscal FY 2020): 20 published measures, 34 facts as tagged in accession 0001213900-21-019097.

This filing

Form: 10-K (annual report)
Filed: 2021-03-31
Fiscal period: fiscal FY 2020
Accession: 0001213900-21-019097 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REVELATION BIOSCIENCES, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2020-12-31	74,162,206	USD
At 2019-12-31	22,671	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2020-12-31	2,945,032	USD
At 2019-12-31	26,309	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2020-12-31	5,000,002	USD
At 2019-12-31	-3,638	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2020-12-31	11,734	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	-136,408	USD	366
2019-11-20 to 2019-12-31	-3,638	USD	42
2019-01-01 to 2019-12-31	-3,638	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	-218,713	USD	366

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	74,268,480	USD	366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	-74,038,033	USD	366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2020-12-31	-140,046	USD
At 2019-12-31	-3,638	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2020-12-31	651,291	USD
At 2019-12-31	22,671	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2020-12-31	33,772	USD
At 2019-12-31	26,309	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	145,492	USD	366
2019-11-20 to 2019-12-31	3,638	USD	42

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2020-12-31	2,541,533	shares
At 2019-12-31	0	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2020-12-31	5,137,506	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2020-12-31	33,772	USD
At 2019-12-31	16,309	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2020-12-31	35,000	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	-136,408	USD	366
2019-11-20 to 2019-12-31	-3,638	USD	42

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	-136,408	USD	366
2019-11-20 to 2019-12-31	-3,638	USD	42

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	145,492	USD	366
2019-11-20 to 2019-12-31	3,638	USD	42

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2020-01-01 to 2020-12-31	9,084	USD	366

Inspect the source

Entity: REVELATION BIOSCIENCES, INC. / CIK 0001810560
Captured: 2026-09-21T17:28:29.970Z
SEC response SHA-256: 3c621a17f8feccb2c9e0b1139c88535009e64d83a51f480e7a99d4a19cbf9b74

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001810560.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))